• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Ovid Therapeutics Inc.

    5/14/24 5:19:51 PM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OVID alert in real time by email
    S-8 1 d836127ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on May 14, 2024

    Registration No. 333-   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Form S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Ovid Therapeutics Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   46-5270895

    (State or other jurisdiction of

    incorporation or organization)

     

    (IRS employer

    identification number)

    441 Ninth Avenue, 14th Floor

    New York, New York

     

    10001

    (Address of Principal Executive Offices)   (Zip Code)

     

     

    2017 Equity Incentive Plan

    (Full title of the plan)

    Jeremy M. Levin, DPhil, MB BChir

    Chief Executive Officer

    Ovid Therapeutics Inc.

    441 Ninth Avenue, 14th Floor New York, New York 10001

    (646) 661-7661

    (Name, address, including zip code and telephone number, including area code, of agent for service)

    Copies to:

     

    Thomas M. Perone

    General Counsel and Secretary

    Ovid Therapeutics Inc.

    441 Ninth Avenue, 14th Floor New York, New York 10001

    (646) 661-7661

     

    Laura A. Berezin

    Jaime L. Chase

    Cooley LLP

    1700 Seventh Avenue, Suite 1900

    Seattle, Washington 98101

    (206) 452-8700

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large Accelerated Filer   ☐    Accelerated Filer   ☐
    Non-accelerated Filer   ☒    Smaller Reporting Company   ☒
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    PART I

    EXPLANATORY NOTE

    Ovid Therapeutics Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 (the “Registration Statement”) for the purpose of registering an additional 3,534,599 shares of common stock under the Ovid Therapeutics Inc. 2017 Equity Incentive Plan (the “Plan”), pursuant to the provision of the Plan which provides for annual automatic increases in the number of shares of common stock reserved for issuance under the Plan.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3.

    Incorporation of Documents by Reference.

    The Registrant hereby incorporates by reference into this Registration Statement the following documents filed by it with the Securities and Exchange Commission (the “Commission”):

     

      (a)

    the contents of the Registrant’s Registration Statements on Form S-8, previously filed with the Commission on May 22, 2017 (File No. 333-218167), March 29, 2018 (File No. 333-224033), August 7, 2019 (File No. 333-233101), March 11, 2020 (File No. 333-237098), March 17, 2021 (File No. 333-254420), March 15, 2022 (File No. 333-263562), as amended by that certain Post-Effective Amendment No. 1, dated March  16, 2022 (File No. 333-263562) and May 5, 2023 (File No. 333-271704);

     

      (b)

    the Registrant’s Annual Report on Form 10-K (File No. 001-38085) for the year ended December  31, 2023, filed with the Commission on March 8, 2024 (the “Annual Report”);

     

      (c)

    the information specifically incorporated by reference to the Annual Report from the Registrant’s Definitive Proxy Statement on Schedule 14A (File No.  001-38085), filed with the Commission on April 24, 2024; and

     

      (d)

    the description of our common stock set forth in our registration statement on Form 8-A (File No. 001-38085), filed with the Commission on May  4, 2017, including any amendments thereto or reports filed for the purposes of updating this description, including Exhibit 4.2 to our Annual Report.

    All documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to specific sections of such documents as set forth therein. The Registrant is not, however, incorporating by reference any documents or portions thereof, whether specifically listed above or filed in the future, that are not deemed “filed” with the Commission, including any information furnished pursuant to Items 2.02 or 7.01 of Form 8-K or related exhibits furnished pursuant to Item 9.01 of Form 8-K. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

     

    Item 8.

    Exhibits.

     

    Exhibit
    Number
      

    Exhibit Description

     4.1    Amended and Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38085), filed with the Commission on May 14, 2017).
     4.2    Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock, as corrected (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-38085), filed with the Commission on September 24, 2019).
     4.3    Amended and Restated Bylaws (incorporated herein by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-38085), filed with the Commission on May 14, 2017).
     4.4    2017 Equity Incentive Plan (incorporated herein by reference to Exhibit 4.12 to the Registrant’s Registration Statement on Form S-8 (File No. 333-218167), filed with the Commission on May 22, 2017).


     4.5    Forms of Option Grant Notice and Option Agreement under 2017 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.3 to the Registrant’s Registration Statement on Form S-1 (File No. 333-217245), filed with the Commission on April 18, 2017).
     4.6    Form of Restricted Stock Unit Grant Notice and Award Agreement under the 2017 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 333- 38085), filed with the Commission on May 14, 2024).
     5.1    Opinion of Cooley LLP.
    23.1    Consent of Independent Registered Public Accounting Firm.
    23.2    Consent of Cooley LLP (included in Exhibit 5.1).
    24.1    Power of Attorney (included on the signature page to this Registration Statement).
    107    Filing fee table.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York on May 14, 2024.

     

    Ovid Therapeutics Inc.
    By:  

    /s/ Jeremy M. Levin, DPhil, MB BChir

      Jeremy M. Levin, DPhil, MB BChir
      Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jeremy M. Levin, DPhil, MB BChir and Jeffrey Rona, and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

      

    Title

      

    Date

    /s/ Jeremy M. Levin, DPhil, MB BChir

    Jeremy M. Levin, DPhil, MB BChir

      

    Chief Executive Officer and Director

    (Principal Executive Officer)

       May 14, 2024

    /s/ Jeffrey Rona

    Jeffrey Rona

      

    Chief Business and Financial Officer

    (Principal Financial and Accounting Officer)

       May 14, 2024

    /s/ Karen Bernstein, PhD

    Karen Bernstein PhD

       Director    May 14, 2024

    /s/ Barbara Duncan

    Barbara Duncan

       Director    May 14, 2024

    /s/ Bart Friedman

    Bart Friedman

       Director    May 14, 2024

    /s/ Kevin Fitzgerald, Ph.D.

    Kevin Fitzgerald, Ph.D.

       Director    May 14, 2024

    /s/ Michael Poole, M.D., FACP

    Michael Poole, M.D., FACP

       Director    May 14, 2024
    Get the next $OVID alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OVID

    DatePrice TargetRatingAnalyst
    12/11/2025$3.00Buy
    Roth Capital
    11/17/2025Outperform
    Leerink Partners
    10/9/2025$7.00Outperform
    Oppenheimer
    8/8/2025$3.00Buy
    B. Riley Securities
    6/18/2024Outperform → Perform
    Oppenheimer
    4/30/2024$9.00Buy
    B. Riley Securities
    4/29/2024$9.00Buy
    H.C. Wainwright
    4/5/2024$8.00Outperform
    Wedbush
    More analyst ratings

    $OVID
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by President and CEO Alexander Margaret A.

    4 - Ovid Therapeutics Inc. (0001636651) (Issuer)

    1/5/26 5:55:06 PM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Levin Jeremy M converted options into 71,000 shares, increasing direct ownership by 2% to 3,687,715 units (SEC Form 4)

    4 - Ovid Therapeutics Inc. (0001636651) (Issuer)

    12/18/25 4:15:07 PM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Friedman Bart

    4 - Ovid Therapeutics Inc. (0001636651) (Issuer)

    6/18/25 4:45:09 PM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OVID
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and COO Alexander Margaret A. bought $4,971 worth of shares (6,810 units at $0.73), increasing direct ownership by 24% to 34,935 units (SEC Form 4)

    4 - Ovid Therapeutics Inc. (0001636651) (Issuer)

    1/29/25 9:18:08 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Levin Jeremy M bought $50,364 worth of shares (18,248 units at $2.76), increasing direct ownership by 0.51% to 3,616,715 units (SEC Form 4)

    4 - Ovid Therapeutics Inc. (0001636651) (Issuer)

    3/20/24 5:22:00 PM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OVID
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Ovid Therapeutics Inc.

    SCHEDULE 13G - Ovid Therapeutics Inc. (0001636651) (Subject)

    1/8/26 11:56:04 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Ovid Therapeutics Inc.

    SCHEDULE 13G - Ovid Therapeutics Inc. (0001636651) (Subject)

    1/5/26 4:12:39 PM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Ovid Therapeutics Inc.

    EFFECT - Ovid Therapeutics Inc. (0001636651) (Filer)

    12/23/25 12:15:24 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OVID
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)

    OV350 showed a good safety profile, supporting the advancement of the Company's KCC2 portfolio, including the first oral direct activator, OV4071There were no treatment-related laboratory findings, no safety findings, and no treatment-related serious adverse events (SAEs)Exploratory quantitative electrophysiology results suggest OV350 had central activity and spectral power consistent with expected physiological effects of KCC2 modulation; aligned with expected drug exposure in the brainPharmacokinetics for OV350 were as predicted, and will inform dosing strategies for future KCC2 development programsOV4071 (oral) is on track for regulatory submission for a Phase 1/1b clinical trial in Q1 20

    12/18/25 8:00:00 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer

    NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N., as Chief Medical Officer. Dr. Kaufmann joins Ovid's leadership team with responsibility for guiding clinical, medical, and regulatory strategy as the Company progresses a clinical pipeline of potential best- and first-in-class therapeutic candidates for conditions and symptoms driven by neuronal imbalance. Dr. Kaufmann brings extensive experience developing CNS therapeutics from first-in-human studies through to global regula

    12/2/25 7:00:00 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds

    NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today announced that it has entered into a securities purchase agreement for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of up to $175 million to the Company, including initial gross proceeds of approximately $81 million, in each case before placement agent fees and offering expenses. The PIPE financing is expected to close on or about October 6, 2025, subject to satisfaction of customary closing conditions. The PIPE financing

    10/3/25 7:05:00 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OVID
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on Ovid Therapeutics with a new price target

    Roth Capital initiated coverage of Ovid Therapeutics with a rating of Buy and set a new price target of $3.00

    12/11/25 9:12:49 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Ovid Therapeutics

    Leerink Partners initiated coverage of Ovid Therapeutics with a rating of Outperform

    11/17/25 9:41:02 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Ovid Therapeutics with a new price target

    Oppenheimer initiated coverage of Ovid Therapeutics with a rating of Outperform and set a new price target of $7.00

    10/9/25 8:28:36 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OVID
    Leadership Updates

    Live Leadership Updates

    View All

    Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer

    NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N., as Chief Medical Officer. Dr. Kaufmann joins Ovid's leadership team with responsibility for guiding clinical, medical, and regulatory strategy as the Company progresses a clinical pipeline of potential best- and first-in-class therapeutic candidates for conditions and symptoms driven by neuronal imbalance. Dr. Kaufmann brings extensive experience developing CNS therapeutics from first-in-human studies through to global regula

    12/2/25 7:00:00 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

    NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need, today announced the appointment of Stelios Papadopoulos, Ph.D. to its Board of Directors. "Stelios is a pioneering force in biotechnology. His vision and strategic acumen have shaped the landscape of our industry—building companies, financing breakthroughs, and enabling transformative medicines. We are honored to welcome him to our Board at a defining moment for Ovid," said Jeremy Levin, D.Phil, MB BChir, Chairman and CEO of Ovid Therapeutics. "With our advancing pipeline, including

    3/3/25 8:00:00 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer

    NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced the appointment of Amanda Banks, M.D., as Chief Development Officer. Dr. Banks will oversee Ovid's clinical development, medical, and regulatory affairs functions as well as drive corporate development strategy and execution in partnership with the Company's leadership team. Dr. Banks brings to Ovid broad and deep experience in neurology, clinical strategy, and business development. Her strategic acumen will serve Ovid at an important juncture for the Company as it determ

    8/8/24 8:00:00 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OVID
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ovid Therapeutics Inc.

    SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)

    11/14/24 6:01:44 PM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ovid Therapeutics Inc.

    SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)

    11/14/24 4:39:42 PM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Ovid Therapeutics Inc. (Amendment)

    SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)

    2/14/24 4:15:31 PM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OVID
    Financials

    Live finance-specific insights

    View All

    Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

    An expansive biomarker study confirmed OV329 delivered statistically significant inhibition of GABA-AT as measured across multiple metricsOV329 matched or exceeded inhibition demonstrated by therapeutic doses of first-generation GABA-AT inhibitor, vigabatrin (VGB), as measured on transcranial magnetic stimulation (TMS) 1Findings confirm OV329 penetrates the brain, engages the target and achieves biological modulation as expected of elevated levels of GABA, the major inhibitory neurotransmitterSafety and tolerability results are supportive of further development and appear to be preferable relative to marketed anti-seizure medicines (ASMs)Ovid plans to advance OV329 into a Phase 2a study in d

    10/3/25 7:00:00 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ligand Reports Second Quarter 2024 Financial Results

    Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti

    8/6/24 4:01:00 PM ET
    $AGEN
    $AMGN
    $CASI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations